详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

A trial of arbidol hydrochloride in adults with COVID-19

84| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：领军期刊 ◇ 中华系列

作者：

单位： [1]Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China. [2]institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China. [3]Department of Emergency, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China. [4]Department of Respiratory and Critical Care Medicine, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China. [5]Department of Neurology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430030,China. [6]Department of Respiratory and Critical Care Medicine, Renmin Hospital, Wuhan University, Wuhan, Hubei 430060, China. [7]Department of Endocrinology, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China. [8]Department of Respiratory Medicine, Wuhan Bauhinia Hospital, Wuhan, Hubei 430062, China. [9]Department of Respiratory Medicine, Guanggu Hospital District, The Third Hospital of Wuhan, Wuhan, Hubei 430074, China. [10]Department of Respiratory and Critical Care Medicine, Puren Hospital, Wuhan University of Science and Technology, Wuhan, Hubei 430081, China. [11]Department of Respiratory Medicine, The Third People's Hospital of Hubei Province, Wuhan, Hubei 430030, China. [12]Department of Respiratory Medicine, The Sixth General Hospital of Hubei Province, Wuhan, Hubei 430015, China. [13]Tuberculosis Department of Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan 610066, China. [14]Department of Neurology, Wuhan Red Cross Hospital, Wuhan, Hubei 430015, China. [15]Department of Tuberculosis, Jinyintan Hospital, Wuhan, Hubei 430048, China. [16]Department of Cardiology, The Third People's Hospital of Hubei Province, Wuhan, Hubei 430030, China.

出处：

DOI：

ISSN：

关键词： Arbidol Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

摘要：

To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19.This was a prospective, open-label, controlled and multicenter investigator-initiated trial involving adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients were stratified 1:2 to either standard-of-care (SOC) or SOC plus arbidol tablets (oral administration of 200 mg per time, three times a day for 14 days). The primary endpoint was negative conversion of SARS-CoV-2 within the first week. The rates and 95% confidential intervals were calculated for each variable.A total of 99 patients with laboratory-confirmed SARS-CoV-2 infection were enrolled; 66 were assigned to the SOC plus arbidol tablets group, and 33 to the SOC group. The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group (70.3% [45/64] vs. 42.4% [14/33]; difference of conversion rate 27.9%; 95% confidence interval [CI], 7.7%-48.1%; P = 0.008). Compared to those in the SOC group, patients receiving arbidol tablets had a shorter duration of clinical recovery (median 7.0 days vs. 12.0 days; hazard ratio [HR]: 1.877, 95% CI: 1.151-3.060, P = 0.006), symptom of fever (median 3.0 days vs. 12.0 days; HR: 18.990, 95% CI: 5.350-67.410, P < 0.001), as well as hospitalization (median 12.5 days vs. 20.0 days; P < 0.001). Moreover, the addition of arbidol tablets to SOC led to more rapid normalization of declined blood lymphocytes (median 10.0 days vs. 14.5 days; P > 0.05). The most common adverse event in the arbidol tablets group was the elevation of transaminase (5/200, 2.5%), and no one withdrew from the study due to adverse events or disease progression.SOC plus arbidol tablets significantly increase the negative conversion rate of SARS-CoV-2 within the first week anas, accelerate the recovery of COVID-19 patients. During the treatment with arbidol tablets, we find no significant serious adverse events.Chinese Clinical Trial Registry, NCT04260594, www.clinicaltrials.gov/ct2/show/NCT04260594?term=NCT04260594&draw=2&rank=1.Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 3 区医学：内科

最新[2025]版：

大类 | 2 区医学

小类 | 2 区医学：内科

JCR分区：

出版当年[2020]版：

Q2 MEDICINE, GENERAL & INTERNAL

最新[2023]版：

Q1 MEDICINE, GENERAL & INTERNAL

影响因子： 7.5 最新[2023版] 4.9 最新五年平均 2.628 出版当年[2020版] 2.361 出版当年五年平均 1.585 出版前一年[2019版] 6.133 出版后一年[2021版]

第一作者：

第一作者单位： [1]Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China. [2]institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.

通讯作者：

通讯机构： [1]Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China. [2]institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China. [*1]Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

A trial of arbidol hydrochloride in adults with COVID-19

文献详情

相关文献